Newer therapies for osteoporosis

Chandrasekar Palaniswamy1, Dhana Rekha Selvaraj, Varuni Rao

  • 1Department of Medicine, New York Medical College, New York, Valhalla, NY, USA. drpchandrasekar@gmail.com

Insights

Current osteoporosis treatments have limitations. Emerging therapies target osteoclasts and osteoblasts, offering new hope for improved osteoporosis management and treatment efficacy.

Area of Science:

  • Bone biology and pharmacology
  • Drug discovery and development

Background:

  • Existing osteoporosis drugs have limited efficacy and tolerability.
  • Osteoporosis treatment requires novel therapeutic strategies.

Purpose of the Study:

  • To review emerging molecular targets for osteoporosis treatment.
  • To discuss novel drug candidates currently in clinical development.

Main Methods:

  • Literature review of current and emerging osteoporosis therapies.
  • Analysis of molecular targets for osteoclast and osteoblast modulation.

Main Results:

  • Several novel drug classes are under clinical investigation.
  • Targeting the receptor activator of nuclear factor kappaB (RANK) pathway, Cathepsin K, and integrins are key osteoclast-targeted strategies.
  • Wnt signaling pathway modulators, such as sclerostin antagonists, represent promising osteoblast-targeted therapies.

Conclusions:

  • Emerging osteoporosis drugs show potential for improved treatment outcomes.
  • Targeting specific molecular pathways in osteoclasts and osteoblasts offers new therapeutic avenues.

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...